In the transgenic mouse model of PD, oral administration of NPT200-11 demonstrated its capability to penetrate the blood–brain barrier and exert beneficial effects on neuropathological and behavioral outcomes by reducing α-synuclein aggregation (Price et al., 2018). This evidence concerns the gene SNCA and Parkinson disease.